Bio-Technology General Corp. (BTGC)
Stuart Weisbrod of Merrill Lynch began coverage with a "hold." Weisbrod views the company as a successful turnaround that appears poised to begin generating earnings by the second half of 1994. "Our long-term Neutral rating belies our enthusiasm for earnings acceleration," he said. While the stock is undervalued, patent